Publications – Peter Nygren

Publications in DiVA

Publications in PubMed

Selected publications:

  1. Andersson CR, Selvin T, Blom K, Rubin J, Berglund M, Jarvius M, Lenhammar L, Parrow V, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway: new treatment for diseases with defective ERK signaling. Scientific Rep, in press, 2020.
  2. Karlsson H, Senkowski W, Fryknäs M, Mansoori S, Linder S, Gullbo J, Larsson R, Nygren P. A novel spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation. Oncotarget 2019, 10: 5372-5382.
  3. Rubin J, Mansoori S, Blom K, Berglund M, Lenhammar L, Andersson C, Loskog A, Fryknäs M, Nygren P, Larsson R. Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activatin and tumour cell killing. Oncotarget 2018, 9, 30805.
  4. Daskalakis K, Norlén O, Karakatsanis A, Hellman P, Larsson, Nygren P*, Stålberg P*. Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors. Endocrin Relat Cancer 2018, 25: 471.
  5. Blom K, Nygren P, Larsson R and Andersson C. Predictive value of ex vivo chemosensitivity assays for individualized cancer chemotherapy: a meta analysis. SLAS Technol 2017, 22: 306, 2017.
  6. Karlsson H, Fryknäs M, Strese S, Gullbo J, Westman G, Bremberg U, Sjöblom T, Pandzic T, Larsson R, Nygren P. Mechanistic characterisation of a copper containing thiosemicarbazone with potent antitumor activity. Oncotarget, 2017, 10.18632.
  7. Blom K, Nygren P, Alvarsson J, Larsson R, Andersson C. Ex vivo assessment of drug activity in patient tumor cells as a basis for tailored cancer therapy. J Lab Autom 21: 178-87, 2016.
  8. Bjersand K, Mahteme H, Sundström Poromaa I, Andréasson H, Graf W, Larsson R, Nygren P. Drug sensitivity testing in cytoreductive surgery and intraperitoneal chemotherapy of pseudomyxoma peritonei. Ann Surg Oncol 2015, 22: S810-16.
  9. Lubberink M, Golla S, Jonasson M, Rubin K, Glimelius B, Sörensen J, Nygren P. 15O water PET study of the effect of imatinib, a selective platelet-derived growth factor receptor inhibitor, versus anakinra, an IL-R antagonist, on water perfusable tissue fraction in colorectal cancer metastases. J Nucl Med 2015, 56: 1144-1149.
  10. Karlsson H, Fryknäs M, Larsson R, Nygren P. Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res 2012, 318: 1577-1585.